# Sequential Paclitaxel Plus Cisplatin Chemotherapy and Radiotherapy as 1st Line Treatment for Esophageal Squamous Cell Cancer

> **NCT02016274** · PHASE2 · UNKNOWN · sponsor: **Shen Lin** · enrollment: 70 (estimated)

## Conditions studied

- Esophageal Squamous Cell Cancer

## Interventions

- **OTHER:** Sequential chemotherapy (paclitaxel 175mg/m2 d1; cisplatin 37.5mg/m2 d1,d2) and radiotherapy

## Key facts

- **NCT ID:** NCT02016274
- **Lead sponsor:** Shen Lin
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-12
- **Primary completion:** 2015-12
- **Final completion:** 2016-07
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2013-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02016274

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02016274, "Sequential Paclitaxel Plus Cisplatin Chemotherapy and Radiotherapy as 1st Line Treatment for Esophageal Squamous Cell Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02016274. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*